AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
Rhea-AI Summary
AccuStem Sciences (OTCQB: ACUT) executed a pilot study agreement with NSABP to evaluate the StemPrintER test in a subset of patients from the NSABP B-32 cohort. StemPrintER interrogates 20 genes to stratify early-stage breast cancer patients by tumor "stemness" to assess recurrence risk. Prior studies cited show "High Stemness" patients are up to 4x more likely to experience distant recurrence than "Low Stemness" patients. The pilot will assess sample viability and predictive utility in the surgical setting and enable subsequent confirmation across the full B-32 cohort of over 5,000 enrolled patients.
Positive
- Executed a pilot study agreement with NSABP to evaluate StemPrintER
- StemPrintER analyzes 20 genes to stratify recurrence risk
- Prior studies reported High Stemness up to 4x distant recurrence risk
- Study uses B-32 cohort that enrolled over 5,000 patients
Negative
- Pilot studies evaluate a subset only; full-cohort validation required
- No timeline or quantitative commercial impact disclosed
- No financial terms or funding details provided for the study
News Market Reaction
On the day this news was published, ACUT gained 15.97%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Initial study will enable further collaboration on the predictive capabilities of StemPrintER
PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a subset of patients from the B-32 cohort. This evaluation will enable the two groups to then confirm the predictive capabilities of StemPrintER across the full study cohort.
The StemPrintER test interrogates 20 genes to stratify patients with early stage breast cancer according to their recurrence risk. The test was designed to measures the “stemness” of tumors, or how much they behave like stem cells, which may indicate the likelihood of cancer progression and response to standard treatment modalities. Studies have shown that StemPrintER is highly prognostic, with “High Stemness” patients up to 4 times as likely to experience a distant recurrence as “Low Stemness” patients.
“We have a strong foundation of evidence demonstrating the prognostic utility of StemPrintER,” said Wendy Blosser, Chief Executive Officer of AccuStem. “Preliminary in silico work has shown that StemPrintER likely has predictive utility in the surgical setting, so we are partnering with the NSABP - the leader in breast cancer research - to validate those findings. We believe that positive study results could have far-reaching implications for surgical planning in breast cancer.”
The NSABP B-32 trial, which enrolled more than 5,000 patients from 1999 through 2004, was a prospective, randomized study that compared sentinel lymph node resection (SLNR) alone to full axillary lymph node dissection (ALND) for women with early stage breast cancer. The trial found that SLNR alone was equivalent in overall survival and regional control to ALND but resulted in fewer side effects such as nerve damage and lymphedema. Importantly, while patient outcomes on a population level are similar between both study groups, it is reasonable to expect there are a subset of patients who would derive a clinically meaningful benefit from ALND versus SLNR. Thus, this pilot and the larger study represent an ideal opportunity to evaluate sample viability and StemPrintER’s ability to support more informed surgical planning for patients with early stage breast cancer.
“Working with NSABP to identify an unanswered clinical question with potential for a meaningful impact on patient outcomes and treatment planning led us to the B-32 cohort,” said Ms. Blosser. “The NSABP has been on the forefront of innovation in breast cancer care, and we look forward to reporting on the findings of this study.”
For more information on StemPrintER, visit AccuStem.com.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. AccuStem Sciences, Inc. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Contact:
Jeff Fensterer
Email: investors@accustem.com
FAQ
What did AccuStem (ACUT) announce about StemPrintER on January 8, 2026?
What does the StemPrintER test measure and how many genes does it use for ACUT?
Why is the NSABP B-32 cohort relevant to AccuStem's pilot study (ACUT)?
Does the press release report StemPrintER predictive results for surgical planning for ACUT?
How strong is the existing evidence cited by AccuStem for StemPrintER (ACUT)?
